RIBAVIRIN ELAIDATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H44N4O6
Molecular Weight	508.6508
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC(=N2)C(N)=O

InChI

InChIKey=HNJWVTLAOZFLEK-OOWZQQDUSA-N

InChI=1S/C26H44N4O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(31)35-18-20-22(32)23(33)26(36-20)30-19-28-25(29-30)24(27)34/h9-10,19-20,22-23,26,32-33H,2-8,11-18H2,1H3,(H2,27,34)/b10-9+/t20-,22-,23-,26-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C26H44N4O6
Molecular Weight	508.6508
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://link.springer.com/content/pdf/10.1038%2Fscibx.2013.652.pdf |https://www.thailandmedical.news/pages/health/ribavirin-marketing | https://www.thepharmaletter.com/company/clavis-pharma

Ribavirin elaidate (CP-4033; TRX-201), a Lipid Vector Technology derivative of ribavirin. It inhibits elongation factor F4E (elF4E), which stimulates cell growth. Translational Therapeutics Inc. received orphan drug status from the U.S. Food and Drug Administration (FDA) in 2011 for ribavirin elaidate in the treatment of aggressive follicular, medullary and anaplastic thyroid carcinoma.

Originator

Approval Year

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:07:20 GMT 2025` Edited by `admin` on `Mon Mar 31 21:07:20 GMT 2025`
Record UNII	4LU13X0I13
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE, 1-(5-O-((9E)-1-OXO-9-OCTADECEN-1-YL)-.BETA.-D-RIBOFURANOSYL)-

Preferred Name

English

RIBAVIRIN ELAIDATE

Common Name

English

RIBAVIRIN-5'-ELAIDIC ACID ESTER

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

344011